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Abstract
Background: Determination of HIV-1 co-receptor use is a necessity before initiation of a CCR5 antagonist but the
longevity of a CCR5-use prediction remains unknown.
Methods: Genotypic co-receptor tropism determination was performed in 225 newly diagnosed individuals consulting
an AIDS Reference Centre. Samples were collected at diagnosis and at initiation of antiretroviral therapy or just
before closure of the study for patients who did not initiate therapy. For individuals with a discordant tropism
prediction on the two longitudinal samples, analysis of intermediate samples and single genome sequencing of
proviral DNA was performed to confirm the tropism switch. Deep sequencing was done to identify minor CXCR4 or
CCR5-using populations in the initial sample.
Results: Overall, tropism switches were rare (7.6%). Only a geno2pheno false positive rate of <50% at baseline was
retained as predictive for a subsequent switch from CCR5-use only to predicted CXCR4-use. Minor CXCR4-using
virus populations were detected in the first sample of 9 of the 14 R5-to-X4 switchers but the subsequent outgrowth of
these minor populations was documented in only 3.
Conclusions: With the current guidelines for treatment initiation at CD4+ T cell counts of <500 cells/mm3, co-receptor
switch between diagnosis and starting antiretroviral therapy is rare. Patients with R5 viruses and a geno2pheno FPR
of <50% are more prone to subsequent co-receptor switch than patients with an FPR of >50% and will need repeat
tropism testing if initiation of maraviroc is considered and previous testing dates from more than a year before.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) is
dependent on binding to the CD4 receptor and a co-receptor,
either CCR5 or CXCR4, for entry into target cells. The
development of entry inhibitors has increased interest in co-
receptor affinity or tropism. The only entry inhibitor currently
FDA/EMA approved is the CCR5 antagonist maraviroc. This
drug can be initiated only after excluding the presence of virus
able to use CXCR4. Phenotypic as well as genotypic assays
have been developed for co-receptor tropism analysis and both
can be used to screen for maraviroc sensitivity [1,2].
Depending on the geographical region phenotypic or genotypic
methods are more widely used.
In recently infected individuals in general CCR5-using (R5)
variants are found. Progression of the infection can lead to the
occurrence of CXCR4-using (X4) strains [3,4]. In the absence
of combination antiretroviral therapy (ART) and in treatment
experienced patients with a history of therapy failure, co-
receptor switch has been observed in approximately half of
subtype B infected individuals [5-9]. Detection of X4 variants is
associated with accelerated CD4 decline, increased plasma
HIV-1 RNA levels and hence with a faster disease progression
[8,10-14]. The mechanism behind co-receptor switch is still
largely unknown and the question whether co-receptor switch
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is cause or consequence of the accelerated disease
progression remains unanswered.
Data suggests that the risk for tropism switch over time in
patients with suppressed viremia is extremely low [15,16], but
adequate data on the risk for a co-receptor switch pre-ART in
the current era with relatively early start of medication, are still
limited [17]. As a result, the DHHS guidelines and the
European guidelines on tropism testing in clinical management
of HIV-1 infected patients are unable to provide guidance on
the durability of an R5 result [1,2].
The study described aimed at determining the prevalence of
co-receptor switch over time in ART-naive individuals and at
determining potential viral or patient characteristics that predict
co-receptor switch. The results showed that pre-ART co-
receptor tropism switch is rare. Only the false positive rate
(FPR) of the geno2pheno co-receptor tropism prediction tool
could be retained as predictive for faster co-receptor switch.
Methods
Ethics statement
The study was approved by the Ethics Committee of the
University Hospital Ghent, EC number 2010/057. All analyses
were performed on rest fractions of stored samples after written
informed consent from the patients. Patient selection as well as
sample analysis was done anonymously, researchers
participating in the project were unable to couple back samples
to original patients.
Study subjects
From 798 patients, newly registered at the AIDS Reference
Centre (ARC) of Ghent University Hospital (Belgium) between
January 2001 and December 2009, 244 patients were
retrospectively selected based on the criteria that the patient
had to be newly diagnosed and that a blood sample, collected
within 1 year of diagnosis, as well as a blood sample collected
at the start of ART or by the end of the study period (August
2011) if no ART was initiated, had to be available. The minimal
time required between the two samples was 3 months.
Information on HIV transmission route, sex, age, origin, CD4+
T-cell count, viral load, and protease (PR) and reverse
transcriptase (RT) resistance were retrieved anonymously from
the patients’ files. Identification of drug resistance in the
protease and reverse transcriptase genes was based on the
Stanford HIV Drug Resistance database v6.2.0 (http://
hivdb.stanford.edu). HIV-1 subtyping was performed using PR
and RT sequences and the Smartgene subtyping tool (IDNS).
Co-receptor tropism determinations
Viral RNA was extracted from EDTA plasma with the High
Pure viral RNA kit (Roche Applied Science). V3 amplification
and population sequencing was performed as described before
[18]. Sequencing products were analyzed on the ABI-Prism
3130XL Genetic Analyzer (Applied Biosystems). Proofreading
was done with Smartgene (IDNS) and subsequently V3
nucleotide sequences were submitted to geno2pheno[co-
receptor]2.0 (http://co-receptor.bioinf.mpi-inf.mpg.de/index.php)
[19]. For classification as CCR5-using (R5) or CXCR4-using
(X4), a false-positive rate (FPR) cut-off of 10% was applied in
accordance with reports describing the use of this method to
predict maraviroc susceptibility [20] and comparisons with
phenotypic assays [21]. All V3 sequences generated for this
study through population or deep sequencing are available on
request.
Single genome sequencing of viral DNA
DNA was extracted from buffy coat cells using the QIAamp
Blood Kit (Qiagen). For each DNA sample a 5- to 200-fold
dilution series was created and several PCR reactions were
run to determine the dilution for which only one third of identical
PCR reactions provided a positive PCR product. Primers and
conditions used for V3 amplifications were the same as the
ones used for V3 amplification from RNA [18]. All individual
PCR products were sequenced and all sequences with no
more than 1 ambiguous nucleotide position were used for co-
receptor tropism prediction.
Deep sequencing of V3
RNA extraction was performed on 200 to 500 µl of plasma,
using the High Pure Viral RNA kit (Roche). 10 µl of extracted
RNA was used in the initial RT-PCR reaction that was
executed as described previously [18]. Amplicons generated
during the RT-PCR reaction were then used as template for the
nested PCR with primers 5’-
TCAACHCAAYTRCTGTTAAATGG-3’ and 5’-
ATTTCTGGRTCYCCKCCTG-3’ extended with Roche MIDs 1
to 8, 10, 11 and 13. The final amplification product spanned
positions 6990 to 7336 (HxB2 numbering) of the envelope
gene. Amplicons were purified using the AMPure XP DNA
purification kit (Agencourt) and quantified using the Qubit
dsDNA HS Assay (Life Technologies).
Emulsion PCR was done with an input of 1.5 copies per
bead with the LibAemPCR kit (Roche). Deep sequencing was
done on the 454 GS Junior platform (Roche) according to the
manufacturer’s instructions. After data processing with the
Roche instrument software, reads that passed the filtering were
submitted to geno2pheno[coreceptor] for tropism prediction. Data to
determine the individual variants was filtered on an average
Phred score above 25 with Mothur software [22] and aligned
using Clustal W (Bioedit). Reads were trimmed to the V3 region
and identical reads were clustered. Reads and their number of
occurrence were listed for each plasma sample. Only variants
with a minimum of 5 reads and representing at least 0.2 % of
the total number of reads that passed the filtering, were
retained.
Phylogenetic analysis
V3 nucleotide sequences were manually aligned using
BioEdit [23]. The best fitting nucleotide-substitution model was
selected according to the Akaike Information Criterium (AIC)
using jModeltest 0.1.1 [24]. Maximum likelihood estimated
distances according to the chosen model, were used to
construct neighbor-joining phylogenetic trees in PAUP*
v4.0b10 (http://paup.csit.fsu.edu/) [25]. Bootstrap analysis was
performed using the above mentioned conditions on 1000
HIV-1 Co-Receptor Switch before ART
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replicates. The tree was rooted using the consensus V3
sequence of subtype B as outgroup. The tree was visualized
using iTOL [26,27].
CCR5 genotyping
To determine the presence of a deleterious 32-base pair (bp)
deletion in CCR5, a fragment flanking the deletion was
amplified from the patients’ genomic DNA after extraction with
QIAamp DNA Blood minikit (Qiagen). Primers and amplification
conditions were depicted by de Roda Husman et al. [5]. The
reverse primer was fluorescently labeled with FAM to allow to
define the length of the amplified products on an ABI-Prism
3130XL Genetic Analyzer (Applied Biosystems): wild type
(wt)/wt: 239 bp, wt/∆32: 239 bp + 207 bp, ∆32/∆32: 207 bp.
Statistical analysis
Groups were compared using a χ2 test for categorical
variables and the Mann-Whitney U nonparametric test for
continuous variables. The level of significance was set at p ≤
0.05. Kaplan-Meier plots were drawn to present the co-receptor
use evolution with time for the different patient groups. All data
were analyzed using SPSS 19.0 software (SPSS).
Results
Co-receptor tropism determination and prevalence of
co-receptor switch
Although the initial selection comprised 244 patients (Figure
1), 19 were omitted from the analysis because of failure to
amplify the V3 loop or bad quality sequencing results. For the
remaining 225 patients, the mean interval between the first and
last sample analyzed was 32 months (IQR: 17-44); 30 months
(IQR: 14-42) for the 183 patients who initiated ART and 42
months (IQR: 22-55) for the 42 patients who remained ART
naive.
Of the 225 patients included in the analysis, 189 (84%) were
initially predicted as CCR5-using (R5) and 36 (16%) were
predicted as CXCR4-using (X4). Analysis of the follow-up
sample revealed that 175 (77.8%) remained CCR5-using
(R5R5 = R5-using in first and second sample) and 33 (14.7%)
remained CXCR4-using (X4X4) (Figure 1). R5X4 or X4R5
predictions were obtained for 17 individuals (7.6%) (Figure 1).
For all 17 patients the tropism switch was confirmed after
repeat analysis in triplicate and additional testing of at least 2
intermediate samples. A switch from CCR5- to CXCR4-use
(R5X4) was seen in 14 individuals (14/189; 7.4%) and a switch
from CXCR4- to CCR5-use (X4R5) in 3 (3/36; 8.3%). There
was no statistical difference between the probability of
switching to X4 after a R5 prediction and the probability of
switching to R5 after an X4 prediction (p = 0.740).
Correlates of CCR5-to-CXCR4 co-receptor switch and
clinical impact
The search for clinical predictive markers for co-receptor
switch concentrated on the comparison between the 175 R5R5
individuals and the 14 R5X4 individuals. All characteristics and
the results of the statistical comparison are shown in Table 1.
No difference between the two groups was seen for age,
gender, race, CCR5 genotype or transmission route, viral
subtype, presence of drug resistance at diagnosis, first viral
load or first CD4 count (p > 0.05). Lower FPR at diagnosis was
seen in the group with R5X4 switch (median 27.4% versus
59.2% for the R5R5 group; p = 0.001). A significant lower CD4
count at ART initiation - but not at diagnosis - was observed in
the R5X4 switchers (p = 0.015). Reanalysis of the data using a
cut-off of 5% FPR instead of 10% FPR did not change the
associations. Patients with an FPR of less than 50% at
diagnosis had a 14% chance to switch co-receptor use over
time compared to 2% for patients with an FPR of more than
50% (p = 0.001) (Figure 2A). Of the 14 patients with an R5X4
switch, the FPR at diagnosis was between 10% and 25% in 7
Figure 1.  Overview of the number of patients included in each step of the analysis for each patient group: R5R5 and X4X4
non switchers, R5X4 and X4R5 switchers.  #: number; ART: initiation of antiretroviral treatment (ART) during the study period; No
ART: ART not initiated at the end of the study period.
doi: 10.1371/journal.pone.0080259.g001
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(50%), between 25% and 50% in 5 (35.7%), between 50% and
75% in 1 (7.1%) and between 75% and 100% in 1 (7.1%).
The Kaplan-Meier plot in Figure 2B illustrates the rate of
tropism switch over time in patients classified according to the
FPR at diagnosis. After 1 year of follow-up no R5X4 switches
were observed (n = 14), after two years the probability of co-
receptor switch was 3.8% in the patients with an FPR between
10% and 25%, 7% in those with an FPR between 25% and
50%, 0% in those with an FPR between 50% and 75% and 0%
in those with an FPR between 75% and 100%. After four years
the probability of switching was 28%, 9.7%, 7.1% and 3.2%,
respectively.
183 of 225 patients (81.3 %) initiated ART during the follow-
up period. ART was initiated in all R5X4 switchers (100%)
compared to 78.3% of the R5R5 individuals (p = 0.077; Table
1). The Kaplan-Meier plot in Figure 2C illustrates the ART
initiation over time. The number of patients initiating therapy
within 2 years of diagnosis is the highest in the X4X4 group.
After approximately 2 years, an increase in number of patients
initiating treatment is observed for the R5X4 individuals, finally
resulting in treatment percentages comparable to the X4X4
Table 1. Comparison of patient and viral characteristics for the R5R5 control group (n=175) and the R5X4 switchers (n=14).
 R5R5 R5X4  
 n (%) n (%) p-value
Patient Characteristics (n = 189) 175 14  
Age, median (IQR), y (n = 189) 40 (34-46) 41 (31-51) 0.788
Gender, No. (%) (n = 189) 175 14  
Male 144 (82.3%) 11 (78.6%) 0.72
Female 31 (17.7%) 3 (21.4%)  
Race or ethnicity, No. (%) (n = 186) 172 14  
Caucasian 145 (84.3%) 14 (100%) 0.228
Other 27 (15.7%) 0 (0.0%)  
Transmission route, No. (%) (n = 170) 158 12  
Homosexual contact 109 (69.0%) 10 (83.3%) 0.514
Heterosexual contact 43 (27.2%) 1 (8.3%) 0.19
Other 6 (3.8%) 1 (8.3%) 0.407
CCR5 genotype, No. (%) (n = 184) 170 14  
wt/wt 144 (84.7%) 13 (92.9%) 0.697
wt/Δ32 26 (15.3%) 1 (7.1%)  
Therapy initiation, No. (%) (n = 189) 175 14  
Yes 137 (78.3%) 14 (100%) 0.077
No 38 (21.7%) 0 (0.0%)  
CD4+ T cell count at diagnosis, Median (IQR),
cells/mm+ (n = 178) 498 (365-653) 491 (339-590) 0.457
CD4 <350 (n = 40) 36 (22.0%) 4 (28.6%) 0.496
CD4 350 - 500 (n = 50) 47 (28.7%) 3 (21.4%) 0.52
CD4 >500 (n = 88) 81 (49.4%) 7 (50.0%) 0.781
Treatment initiation CD4+ T cell count, Median (IQR), cells/mm+ (n = 172) 360 (274-482) 227 (159-409) 0.015
Drug free period, Mean (IQR), months (n = 152) 32 (15-44) 31 (21-38) 0.947
Follow-up period, Mean (IQR), months (n = 189) 35 (19-46) 31 (21-38) 0.703
Viral Characteristics    
Viral load at diagnosis, Median (IQR), log copies/ ml (n = 186) 4.46 (3.95-4.96) 4.43 (3.96-4.77) 0.867
Treatment initiation viral load, Median (IQR), log copies/ ml (n = 183) 4.55 (3.84-4.98) 4.81 (4.24-5.07) 0.297
FPR at diagnosis, Median (IQR), % (n = 189) 59 (31-81) 27 (15-48) 0.001
FPR < 50 (n = 85) 73 (41.7%) 12 (85.7%) 0.001
FPR > 50 (n = 104) 102 (58.3%) 2 (14.3%)  
Transmitted drug resistance, No. (%) (n = 189) 175 14  
Yes 9 (5.1%) 0 (0%) 1,000
No 166 (94.9%) 14 (100%)  
Virus subtype, No. (%) (n = 189) 175 14  
B 128 (74.9%) 11 (78.6%) 0.411
non B 43 (25.1%) 3 (21.4%)  
For classification as R5 or X4, an FPR cut-off of 10% was applied. For each characteristic, only those patients for whom the information was available were included in the
analysis. n: number of included patients; FPR: false positive rate.
doi: 10.1371/journal.pone.0080259.t001
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group. X4X4 patients started ART after a mean of 21 months
(IQR: 12-31), compared to 31 months (IQR:21-38) for the R5X4
group and 35 months (IQR:19-46) for the R5R5 group (p <
0.05). Patients with an R5X4 tropism switch had significantly
lower CD4+ T-cell counts at the time of treatment initiation
compared to the R5R5 patients (median 227 cells/mm3 versus
360 cells/mm3; p = 0.015; Table 1).
Association between the FPR at diagnosis and the
presence of X4 minorities and impact on tropism
switch
To evaluate whether a lower FPR at baseline reflects the
presence of X4 minorities, DS of V3 was performed. Minority
variants were identified in the first sample of 9 of the 14 R5X4
switchers (64.3%) and 2 of the 3 X4R5 switchers (66.6%)
(Table 2).
The number of unique minority sequences per sample varied
between 1 and 5 with a coverage of between 0.23% and 8.09%
of the total number of DS reads for the sample (Table 2). A
higher prevalence of minor X4 variants was noticed in samples
with an FPR of <25% compared to samples with an FPR of
>25% (minority X4 variants in 6/7, 85.7% versus 3/7, 42.9%; p
= 0.056). No minor variants were detected in the 2 patient with
a baseline FPR of >50%.
For each patient with a tropism switch, all V3 sequences
from the DS analysis as well as the V3 sequences obtained
after the single genome sequencing and the V3 sequences
obtained after population sequencing were aligned for
phylogenetic analysis (see Figure 3). The tree topology was
suggestive for the outgrowth of a minority X4 strain over time
for only 3 of the 14 R5X4 patients (21.4%). For 2 of these 3
patients the minority X4 variant was already present at
relatively high frequency in the first sample (6.42% and 8.09%;
Table 2).
V3 mutational patterns of switching patients
In order to define mutations responsible for tropism shifts,
the population V3 sequences of the first and last sample were
compared. The number of amino acid replacements varied
between 1 and 11. The position of the replacements and the
specific substitutions differed between patients but changes at
positions 13, 25, 32 and 34 were most frequently observed.
The Pearson correlation coefficient for the relation between the
FPR and the number of substitutions was calculated but no
correlation was found (p = 0.558). Sequences predicted as
CXCR4-using had an overall higher net charge than sequences
predicted as CCR5-using (mean 6.3 versus 5.0).
Discussion
Current guidelines for tropism testing advise clinicians and
virologists on how to analyse and interpret the results of co-
receptor tropism analyses [1,2]. One question that remains is
whether and after what period of time tropism testing should be
repeated when there is a considerable time delay between
testing and considering the initiation of a CCR5 antagonist.
Overall, the percentage of patients with a tropism switch after
a median follow-up of 32 months was low. Of the 175 patients
initially predicted as exclusively R5, a switch to X4 was seen in
14 (6.2%). Previous studies have reported between 41% and
50% of CXCR4-use in patients with advanced disease
[3,7,12,14,28]. Most of the patients in these studies however
were included approximately 8 to 10 years after infection
[10,29] while the treatment-free follow-up period in our study
Figure 2.  Predictive value of the FPR on co-receptor switch and relation between co-receptor switch and the initiation of
ART.  Figure 2A, Percentage of switching (R5X4) and non-switching patients (R5R5) after classification of the patients in two
groups according to the FPR at diagnosis (10%-50% and 50%-100%). Figure 2B, Kaplan-Meier estimates of the percentage of
CCR5-use over time. Patients were grouped based on the FPR at diagnosis (10%-25%; 25%-50%; 50%-75%; 75%-100%). Each
drop in percentage of CCR5-use reflects a switch to CXCR4-use. n = number of patients in each group. Figure 2C, Kaplan-Meier
estimates of the percentage of therapy naive patients over time for 175 patients with an R5 prediction on both samples (R5R5), 33
patients with an X4 prediction on both samples (X4X4) and 14 patients with a switch from R5 to X4 (R5X4).
doi: 10.1371/journal.pone.0080259.g002
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was much shorter. 81.3% of the studied patients initiated ART
during the study period, 44 (19.8%) in the presence of X4
viruses. If we assume that our patient population reflects the
HIV infected population in many Western countries where
patients are eligible for antiretroviral drugs as soon as the CD4
count has dropped below 500 cells/mm3, the overall
percentage of pre-ART CXCR4-use will most probably not
exceed 20%.
All co-receptor tropism predictions for this study were
performed retrospectively and the outcome was not
communicated to the clinicians. The higher number of
individuals initiating ART in the R5X4 group and in the X4X4
group compared to patients with R5R5 predictions (100%,
90.9% and 78.3% respectively) can therefore only be explained
as a reflection of the worse clinical evolution in these patients.
This confirms the generally accepted association between X4
presence and faster disease progression [8,12,14,30]. Whether
tropism switch induces the faster immune deterioration or
whether X4 viruses can appear because of the decline in
immune function remains a topic of debate. The findings of this
study support the hypothesis that the co-receptor switch
induces the immune decline. Despite identical CD4+ T cell
counts at diagnosis and comparable follow-up time, patients
switching co-receptor use had significantly lower CD4+ T cell
counts at ART initiation compared to patients that remained
R5. Kaplan-Meier plots illustrate the time delay in treatment
initiation between the patients diagnosed with X4 virus and
patients that switch from R5 to X4, but also reveal the
comparable steepness of both curves.
The observation that 3 of the 36 patients predicted as X4 in
the first sample switched to R5 during follow-up is puzzling.
Although some have suggested that after infection with a mixed
population of R5 and X4 strains X4 viruses might be overgrown
by the R5 viruses because they are more prone to CTL
responses [31], the support for this hypothesis is weak. It
remains questionable whether a true shift in tropism from X4 to
R5 can occur and is clinically meaningful. For one X4R5 patient
we have reasons to believe that the patient was re-infected
with an R5 virus after initial infection with an X4 strain but this
remains to be confirmed. Minor R5 sequences were found in
the plasma of the first sample collected from the other 2 X4R5
patients but at very low frequency. In only one patient there
were indications for a later outgrowth of this initial minor R5
variant.
In order to identify possible predictive markers for co-
receptor tropism switch we compared the baseline
characteristics of patients that remained R5 tropic over time
and patients that switched from R5 to X4 tropic. No influence of
age, gender, race, CCR5 genotype, transmission route, viral
subtype, drug resistance, viral load or CD4 count at diagnosis
(p > 0.05) was detected, largely confirming previous findings
[30,32]. The only parameter that came out as predictive for a
subsequent tropism switch was the geno2pheno FPR. Patients
with an FPR of <50% are significantly more prone to co-
receptor switch than patients with an FPR of >50%, which is in
line with previous observations [20]. Little information is
available regarding the value of the FPR apart from it being a
measure to discriminate R5 and X4 predictions when using the




 Patient ID   FPR%
Presence of minority
X4 variants
# of minority X4
variants
# of reads for each
minority variants % of reads
Outgrowth of minority
variants in 2nd sample
R5X4 A 52.5 No 0 0 0 /
 B 89.3 No 0 0 0 /
 C 35.1 Yes 1 11 0.27 N
 E 41.2 Yes 1 27 0.67 N
 F 10.5 Yes 1 11 0.24 N
 G 15 No 0 0 0 /
 H 48 No 0 0 0 /
 I 17 Yes 1 336 6.42 Y
 J 49 No 0 0 0 /
 K 15 Yes 1 10 0.24 /
 L 13.4 Yes 3 303; 55; 52 8.09; 1.47; 1.39 Y
 M 34.6 Yes 3 51; 22; 10 1.37; 0.59; 0.27 N
 O 20.2 Yes 2 12; 11 0.48; 0.44 N
 P 13 Yes 5 17; 10; 9; 7; 7 0.56; 0.33; 0.30; 0.23;0.23 Y
X4R5 D 6.8 Yes 1 13 0.25 /
 N 3.8 No 0 0 0 /
 Q 7.4 Yes 2 23; 9 0.58; 0.23 Y
For each of the 14 R5X4 and 3 X4R5 switching patients the detection of minority X4 or minority R5 variants respectively is indicated as well as the number of minority
variants and the number of reads that this variant represents. # : number; % : percentage.
doi: 10.1371/journal.pone.0080259.t002
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geno2pheno[co-receptor] algorithm. Using DS however, Svicher et
al. demonstrated an association between the FPR and the
burden of minority X4 variants [33]. Our DS results confirmed
this relationship. The importance of minority X4 variants on the
later co-receptor tropism switch however remains questionable.
Phylogenetic analysis provided evidence for the outgrowth of
minority X4 variants over time for 3 of the 14 R5X4 switchers
only, including the 2 patients with the highest X4 burden in the
first sample. In all other R5X4 switchers the tree topology is
more suggestive for evolution from an R5 strain than for the
outgrowth of an existing minor X4 variant.
We next searched for a possible correlation between the
number of V3 amino acid substitutions needed for the evolution
from R5 to X4 and the FPR but were unable to confirm the
hypothesis that a lower FPR reflects a lower genetic barrier for
tropism switch. The precise number and or position of amino
acid replacements needed for switch remains difficult to define
because a high individual variability was observed and tropism
Figure 3.  Neighbor-joining tree illustrating the phylogeny of V3 sequences from 17 co-receptor switchers.  Sequences were
obtained after either population Sanger sequencing on the first (black) and last (grey) plasma sample, deep sequencing on the first
plasma sample (dark green: sequence reads predicted as R5; dark red: sequence reads predicted as X4) or single genome
sequencing performed on cellular DNA from the last sample ( light green: sequences predicted as R5; light red: sequences
predicted as X4). The individual labels contain a patient ID, the sequencing method used to obtain the sequence (S: sanger
sequencing; D: deep sequencing; L: limiting dilution sequencing) and, for the deep sequencing reads, an indication of whether it
was a major read (M; >10% of all reads) or a minor read (m; <10% of all reads).
doi: 10.1371/journal.pone.0080259.g003
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specific mutational patterns could not be defined. The number
of V3 amino acid differences between the first and last sample
in the R5X4 patients varied between 1 and 11, which is in
accordance with the results of others describing that at least 2
mutations are needed for a co-receptor tropism switch [34,35].
Positions 13, 25, 32 and 34 were most frequently mutated. The
involvement of position 25 in co-receptor prevalence has been
recognized long ago but none of the other positions has been
reported as implicating co-receptor affinity [36-40]. Predicted
CXCR4-using V3 sequences also had an overall higher net
positive charge, a specificity also known to be associated with
CXCR4-use [36].
Apart from the FPR, all other parameters for which we
anticipated a possible influence on co-receptor switch lacked
association with early co-receptor switch. Margolis et al. [31]
hypothesized that exhaustion of CCR5 positive target cells or
shortage in CCR5 receptors could facilitate co-receptor switch.
If this hypothesis is true one would expect higher rates of co-
receptor switch in patients heterozygous for the CCR5-∆32
deletion because the defective allele results in a reduced
concentration of CCR5 molecules on the cell surface [41]. In
our patient population however a defective allele was even
more frequent in the R5R5 group than in the R5X4 group
(15.3% vs. 7.1%).
A limitation of this study is the small number of switching
patients that could be included. This may limit the validity of the
statistical analysis whereby potential additional correlates of
CCR5-to-CXCR4 co-receptor switch could have been missed.
Another limitation is that the conclusions are based solely on
genotypic analyses. Many have however reported the excellent
concordance between phenotypic co-receptor tropism
determination and genotypic predictions using geno2pheno
[42,43]. Importantly, the conclusion of this work remained even
after lowering the FPR cut-off from 10% to 5%. An FPR cut-off
of 5% results in a more stringent X4 detection and has been
associated with an overall increase in concordance between
phenotypic co-receptor tropism determination and genotypic
prediction from 85.2% to 91.4% [44]. Also the initial aim of this
study was to define the validity in time of a genotypic tropism
determination as this is the test most commonly used in clinical
practice.
In conclusion, only the FPR result of geno2pheno[co-receptor]
tropism prediction was withheld as a significant predictor of a
subsequent R5 to X4 switch. The findings of this study show
that in patients with R5 prediction at diagnosis and an FPR
above 50%, the probability of tropism switch within 2 to 3 years
is extremely low. Patients infected with a R5 virus and FPR
value below 50% are more prone to co-receptor switch and
need repeat testing if initiation of maraviroc is considered and
co-receptor tropism was defined more than 1 year before.
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